New hope for KRAS G12D lung cancer: targeted drug combo enters trial

NCT ID NCT07554859

Not yet recruiting Disease control Sponsor: Genfleet Therapeutics (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The goal is to see if these treatments shrink tumors and are safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GFH375 (a targeted drug), cetuximab, and pemetrexed
What this could lead to: If successful, this could provide a new first-line treatment option for people with a specific type of advanced lung cancer (KRAS G12D mutation).
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The drug may not work better than existing treatments or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.